Overall rank by patents
#18,012
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Prelude Therapeutics, Incorporated
USPTO PatentsView assignee record - 16 granted patents across 6 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
16
Total patents granted
6
CPC technology areas
29.3
Avg claims per patent
-
5-year filing velocity
The verdict
Prelude holds 16 US patents across 6 technology areas, rank #18,012 of 50,000 tracked assignees.
- #18,012
- of 50,000 US assignees by volume
- Top 20%
- by Innovation Score (46.8/100)
- 29.3
- avg claims per patent
Portfolio overview
Prelude Therapeutics, Incorporated has been granted 16 US utility patents between 2020 and 2025, placing Prelude Therapeutics, Incorporated at rank #18,012 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 29.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Prelude Therapeutics, Incorporated is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 46.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 16 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Prelude Therapeutics, Incorporated's 29.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Prelude Therapeutics, Incorporated against peers pursuing similar technology classes.
How does Prelude compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Prelude Therapeut… ◀ 16
Prelude Therapeutics, Incorporated
16 patents
What this shows Prelude holds 16 patents, placing it at rank #18,012 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Prelude's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
47 Top 20% higher than 80% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2020–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 12.5% |
| 2021 | 3 | 18.8% |
| 2022 | 4 | 25.0% |
| 2023 | 4 | 25.0% |
| 2024 | 2 | 12.5% |
| 2025 | 1 | 6.3% |
Which technologies does Prelude Therapeutics, Incorporated patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Frequently Asked Questions
How many patents does Prelude Therapeutics, Incorporated hold?
Prelude Therapeutics, Incorporated holds 16 US granted patents filed between 2020 and 2025, spanning 6 technology areas.
What is Prelude Therapeutics, Incorporated's Innovation Score?
Prelude Therapeutics, Incorporated has an Innovation Score of 46.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Prelude Therapeutics, Incorporated focus on?
Prelude Therapeutics, Incorporated's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 15 patents. The company has filed patents in 6 CPC subclasses total.
Is Prelude Therapeutics, Incorporated's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Prelude Therapeutics, Incorporated.
What does claim depth mean for Prelude Therapeutics, Incorporated's patents?
Prelude Therapeutics, Incorporated's patents average 29.3 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Prelude Therapeutics, Incorporated patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Prelude's 16 grants land it in the top 20% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Prelude ranks #18,012 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61P technology
Prelude Therapeutics, Incorporated's primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Prelude Therapeutics, Incorporated ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.